Compare INTT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INTT | RFL |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.4M | 133.1M |
| IPO Year | 1997 | 2017 |
| Metric | INTT | RFL |
|---|---|---|
| Price | $14.16 | $1.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 122.2K | 86.5K |
| Earning Date | 11-06-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.23 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,801,000.00 | $917,000.00 |
| Revenue This Year | $22.35 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $263.00 | ★ N/A |
| Revenue Growth | ★ 66.06 | 43.96 |
| 52 Week Low | $7.07 | $1.09 |
| 52 Week High | $20.00 | $3.96 |
| Indicator | INTT | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 29.15 |
| Support Level | $12.54 | N/A |
| Resistance Level | $15.25 | $1.38 |
| Average True Range (ATR) | 0.95 | 0.11 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 49.87 | 1.03 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.